帝奧微(688381.SH):使用募集資金和自有資金向全資子公司增資
格隆匯6月12日丨帝奧微(688381.SH)公佈,公司2025年6月12日召開第二屆董事會第十五次會議、第二屆監事會第十二次會議審議通過了《關於使用募集資金和自有資金向全資子公司增資的議案》,同意公司使用募集資金17,000萬元、自有資金3,000萬元向全資子公司帝奧微(上海)電子科技有限公司(稱“帝奧微(上海)”)增資,其中17,000萬元募集資金用於實施“上海研發檢測中心建設項目”;3,000萬元自有資金用於實施“車規級芯片研發及產業化項目”。增資完成後,帝奧微對帝奧微(上海)的持股比例仍為100%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.